NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
First Quarter 2018 Financial Results to be Announced May 8, 2018
Investor Conference Call to be Scheduled for May 17, 2018 to Discuss Updated Interim Data from Tazemetostat Trials
CAMBRIDGE, Mass., May 01, 2018 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it plans to report the company’s first quarter 2018 financial results on Tuesday, May 8, 2018.
Epizyme also plans to host a conference call and webcast for investors on the morning of May 17, 2018 to discuss recent corporate updates and new tazemetostat clinical data that will be included in upcoming medical meeting abstracts. Details for this call will be provided in the company’s May 8 press release.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program and its next development candidate, EZM8266, is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.
Contacts
Media:
Cheya Pope, Epizyme, Inc.
[email protected]
(617) 229-7561
Investors:
Jason Fredette, Epizyme, Inc.
[email protected]
(617) 500-0623
